Edition:
United Kingdom

Onxeo SA (C4X.PA)

C4X.PA on Paris Stock Exchange

1.60EUR
4:35pm GMT
Change (% chg)

€-0.03 (-1.90%)
Prev Close
€1.63
Open
€1.63
Day's High
€1.63
Day's Low
€1.59
Volume
221,583
Avg. Vol
636,923
52-wk High
€5.46
52-wk Low
€0.98

Chart for

About

Onxeo SA, formerly Bioalliance Pharma SA, is a France-based biopharmaceutical company. In July 2014, the Company, as the continuing entity, merged with Topotarget AS creating Onxeo, a company dedicated to orphan oncology diseases. Onxeo aims at holding a portfolio of advanced programs targeting severe pathologies with unmet... (more)

Overall

Beta: 0.73
Market Cap(Mil.): €88.20
Shares Outstanding(Mil.): 50.69
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.91 10.66
ROE: -- 16.41 14.30

BRIEF-Onxeo Provides Update on Litigation with SpeBio/SpePharm

* ONXEO SA - SUBMITTED CONCLUSIONS TO PARIS COURT OF APPEAL CONCERNING MERITS OF LITIGATION AGAINST SPEPHARM/SPEBIO B.V COMPANIES

23 Jan 2018

BRIEF-Onxeo reports commercial court of Paris decision in lawsuit against SpeBio/SpePharm​

* ‍Onxeo reports first instance decision from commercial court of Paris in lawsuit against SpeBio/SpePharm​

17 Oct 2017

BRIEF-Onxeo introduces chemistry platform of decoy oligonucleotides platON

* ONXEO INTRODUCES PLATON™, A PROPRIETARY CHEMISTRY PLATFORM OF DECOY OLIGONUCLEOTIDES

02 Oct 2017

BRIEF-Onxeo ‍announces preclinical data for combination of AsiDNA™ and belinostat​

* ‍ANNOUNCES COMPELLING PRECLINICAL DATA IN COMBINATION FOR ITS TWO INNOVATIVE COMPOUNDS, ASIDNA™ AND BELINOSTAT​

28 Sep 2017

BRIEF-Onxeo grants exclusive worldwide license for Validive to Monopar Therapeutics

* ONXEO GRANTS EXCLUSIVE WORLDWIDE LICENSE OF VALIDIVE DEVELOPED FOR THE TREATMENT OF ORAL SEVERE MUCOSITIS TO MONOPAR THERAPEUTICS

13 Sep 2017

BRIEF-Onxeo announces top-line results from ReLive Phase III study of Livatag in advanced hepatocellular carcinoma

* Onxeo announces top-line results from ReLive Phase III study of Livatag® in advanced hepatocellular carcinoma

11 Sep 2017

Earnings vs. Estimates